Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report

Table 1 Treatment regimens and response evaluations

No.	Regimen	Dose	Abnormalcells, %	Response
1	Hyper-CVAD	CTX 300 mg/m2 Q12H days 1-3 (mesna rescue); VDS 4 mg day 4, 11; DNR 45 mg/m2 day 1; DEX 40 mg days 1-4, days 11-14	8.1	PR
2	MA	MTX 1.0 g/m2 day 1; Ara-C 2 g/m2 days 2–3 Q12H; methylprednisolone 30 mg/m2 days 1–3
3	Hyper-CVAD	CTX 300 mg/m2 Q12H days 1-3 (mesna rescue); VDS 4 mg days 4, 11; DNR 45 mg/m2 day 1; DEX 40 mg days 1-4, days 11-14	21.42	PD
4	ICE + chidamide	IFO 5 g/m2 day 1, CBP (AUC = 5 mg/mL per min) day 1, VP-16 100 mg/m2 days 3-5, Chidamide: 20mg biw days 1-21	9.94	PR
5	Chidamide	30 mg biw days 1-21	5.6	CR

Cycle length for each course is 21 d; Abnormal cells%: Percentage of atypical lymphocytes as normal lymphocytes analysis by flow cytometric. CR: Complete remission; PR: Partial remission; PD: Progressive disease; Hyper-CVAD: Fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CTX: Cyclophosphamide; VDS: Vindesine; DNR: daunorubicin; DEX: Dexamethasone; MA: Methotrexate, cytarabine, methylprednisolone plus; MTX: Methotrexate; Ara-C: Cytarabine; ICE: Ifosfamide, carboplatin, etoposide; IFO: Ifosfamide; CBP: Carboplatin; VP-16: Etoposide; AUC: AUC is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula.